Clinical trials: open to volunteers, sponsored by AbbVie
Healthy Subjects
A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults
This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.
- Trial name
- NCT07856706
- Testing
- ABBV-7828
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.
- Trial name
- NCT07673120
- Testing
- ABBV-313
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers
This is a Phase 1, open label, five arm study to evaluate the pharmacodynamic effects of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adult participants.
- Trial name
- NCT07843693
- Testing
- Upadacitinib, Tofacitinib, Baricitinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults
The goal of this study is to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1162 in healthy adults.
- Trial name
- NCT07832708
- Testing
- ABBV-1162
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
- Trial name
- NCT07219030
- Testing
- Emraclidine
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.
- Trial name
- NCT07736638
- Testing
- ABBV-859
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
- Trial name
- NCT07466550
- Testing
- Risankizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
- Trial name
- NCT07570147
- Testing
- ABBV-1451
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in…
- Trial name
- NCT07306754
- Testing
- ABBV-243
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AbbVie